Filing Flows › Protalix BioTherapeutics (PLX) › R&D spending
Protalix BioTherapeutics (PLX) R&D spending by quarter
Protalix BioTherapeutics' R&D spending was $4.4M in Q2 2026 (second quarter 2026), -20% from Q1 2026. Over the last 7 quarters it ranged from $3.5M (Q1 2025) to $6.0M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.4M | -20% | -27% |
| Q1 2026 | $5.4M | -4% | +56% |
| Q4 2025 | $5.6M | +26% | +37% |
| Q3 2025 | $4.5M | -25% | — |
| Q2 2025 | $6.0M | +72% | — |
| Q1 2025 | $3.5M | -16% | — |
| Q4 2024 | $4.1M | — | — |
Q2 2026 at a glance
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protalix BioTherapeutics' R&D spending?
Protalix BioTherapeutics' R&D spending was $4.4M in Q2 2026 (second quarter 2026), -20% from Q1 2026.
How has Protalix BioTherapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $3.5M (Q1 2025) to $6.0M (Q2 2025).
Q2 2026 results → · How Protalix BioTherapeutics makes money →